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ABSTRACT 
Myasthenia gravis (MG) is an autoimmune disorder in which patients experience 
weakness of the skeletal or ocular-bulbar muscles. In most patients, anti-AChR 
antibodies affect the signal across the neuromuscular junction necessary for muscular 
contraction. It is a complex disorder, wherein multiple genes plus environmental factors 
are likely necessary for disease manifestation.  
 
IgA deficiency (IgAD) is defined as serum IgA levels less than 0.07 g/l with normal 
levels of IgG and IgM. Due to the role of IgA in mucosal barriers, some patients 
experience recurrent infections, although many individuals are asymptomatic. Both MG 
and IgAD patients experience concomitant autoimmunity more often than in the 
background population, and IgAD may caused by autoimmune mechanisms. 
 
Investigations into genetic associations with MG have targeted genes implicated 
previously in autoimmune disorders. The PTPN22 rs2476601 polymorphism was 
genotyped in 409 MG patients and 1557 controls, and was associated with the entire 
cohort (p=2.7x10
-4
, OR=1.52), as well as with hyperplasia (p=1.4x10
-4
, OR=1.87), anti-
AChR positivity (p=4.9x10
-4
, OR=1.52), and patients exhibiting both (p=6.6x10
-5
, 
OR=1.96). Furthermore, after antigen activation, a significant increase in IL-2 
producing cells (p=0.002) and IgG secreting cells (p=0.004) in patients carrying the T 
allele was observed, indicating that the allele may be a gain-of-function variant in MG. 
 
Genotyping of 446 MG patients and 1866 controls for the CIITA rs3087456 was 
conducted without a statistically significant difference observed between MG patients 
and controls for either allele frequencies (p=0.092) or genotypes (p=0.251). The 
control material differed significantly from the original study reporting association of 
the SNP with several disorders (0.266 and 0.216, respectively, p<10
-5
). A lack of 
association in replication cohorts (4 of 26 reported association) may indicate that the 
SNP does not predispose to autoimmunity. The CD45 SNP rs17612648 was 
genotyped in 446 MG patients and 2303 matched controls, with no association with 
MG (p=0.199). A lack of replication in subsequent studies (4 of 24 reported 
association), as well as the identification of a homozygous blood donor without 
obvious disease, indicates that this SNP’s role in autoimmunity may have to be 
reconsidered. 
 
The HLA A1, B8, DR3, DQ2 (8.1) haplotype has been associated with several 
autoimmune disorders, and homozygosity for this haplotype has been reported to 
impart high risk for IgAD development (RR=77.8). Using 117 identified homozygous 
individuals, 2 were found to be IgAD (1.7%), indicating that the RR for IgAD for such 
carriers is estimated to be 11.89. Despite overlapping 8.1 association in IgAD and MG, 
IgAD is not elevated in MG patients (p=0.14), although concomitant autoimmunity is 
higher than expected in MG (15.9%). The overlapping effects of the haplotype may be 
due to an independent association of B8 in MG. Examining overlapping genes in 
autoimmunity has thus proved to be a valuable method of identifying patterns of 
predisposition.  
 
Using the summary associations to determine complex disease predisposition has 
proven to be difficult. A method was created to use complex disease MZ and DZ twins 
concordance to estimate the frequency of the predisposition (1:5240 in MG) and 
number of overlapping genetic regions contributing to disease (2-4 in MG). This 
information has made it possible to formulate a model of complex disease which is 
flexible to the number of underlying genetic subgroups of disease, and future genetic 
information can be used to predict the probability of disease development. 
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LIST OF ABBREVIATIONS 
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1 INTRODUCTION 
 
1.1 MYASTHENIA GRAVIS 
 
Myasthenia gravis is an autoimmune disorder in which the presence of autoantibodies 
leads to muscular weakness [1]. It was first described by Thomas Willis 1672 in a 
patient exhibiting dysarthia. It was hypothesized to be autoimmune in nature by 
Simpson in 1960 [2], who observed a higher prevalence in females, concomitant 
autoimmunity, and transient neonatal transfer of symptoms. Patrick and Lindstrom 
demonstrated the role of anti-AChR abs in 1973 by observing experimental 
autoimmune MG in rabbits immunized against purified AChRs [3]. 
 
The main symptom of MG is weakness of either skeletal or ocular/bulbar muscles, 
resulting in general weakness, double vision, drooping eyelids, and may result in 
breathing difficulties. Approximately 20% of patients experience a myasthenic crisis, 
defined as the need for mechanical ventilation due to affected breathing muscles, within 
two years of diagnosis [4]. 
 
MG occurs in 14.1 per 100,000 individuals in Sweden [5], and affects females at 
approximately a 2:1 ratio to males. Clinical classifications of MG symptoms by 
Oosterhuis [6] have been reviewed by Jaretzki [7], and are presented in Table 1. 
 
Myasthenia gravis classification scale 
Class I Ocular 
Class II Mild generalized 
         IIa Predominantly skeletal muscle symptoms 
         IIb Predominantly bulbar symptoms 
Class III Moderate generalized 
         IIIa Predominantly skeletal muscle symptoms 
         IIIb Predominantly bulbar symptoms 
Class IV Severe generalized 
         IVa Predominantly skeletal muscle symptoms 
         IVb Predominantly bulbar symptoms 
 
Table 1. Osserman-Oosterhuis classification of MG modified by Jaretzki  
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Patients may have progressive disease or reduction of symptoms with treatment. 
Remission of symptoms is often observed with treatment; however, relapses exist and 
most patients experience fluxuating symptoms throughout their lives. 
 
1.1.1 Disease pathogenesis 
The pathophysiology of myasthenia gravis is located at the neuromuscular junction 
(NMJ), in which nerve impulses are delivered from the CNS to muscle fibers. The 
transmission of the impulses are achieved through secretion of acetylcholine from 
nerve endings, which travel across the junction and bind to receptions situated on the 
muscle fibers. This creates the action potential for muscle contraction. Acetylcholine is 
then rapidly destroyed by acetylcholinesterase, resetting the NMJ for future muscle 
contraction [8]. 
 
 
 
Figure 1. The pathophysiology of anti-AChR abs in MG at the neuromuscular junction. 
Reprinted with permission from [9]. 
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The presence of auto-antibodies against the AChR (anti-AChR abs) may reduce this 
activity by several mechanisms (Figure 1). First, they can cause complement dependent 
lysis of the postsynaptic muscle membrane, leading to a flattening of the postsynaptic 
folds and a reduction in AChR concentration [10]. Second, they cross-link AChRs on 
the membrane surface, which can lead to internalization and degradation, reducing the 
number of AChRs [11]. Last, they can directly block the binding of acetylcholine to the 
receptor [12].  
 
Anti-AChR abs are detected via radioassay [13]. They occur in approximately 80-90% 
of all MG patients, and antibody titers do not correlate to the severity of MG, although 
there is a higher proportion of antibody positivity in more severe forms of the disease 
[13][14]. There is evidence that patients who do not test positive for anti-AChR abs 
may have low affinity antibodies present [15]. Other antibodies found in anti-AChR 
negative patients include anti-MuSK abs, found in approximately 50% of anti-AChR 
abs negative patients, which target another membrane bound receptor in the NMJ [16]. 
However, patients of Swedish origin who are anti-MuSK positive are extremely rare 
[R. Matell]. Antibodies against the striated muscle protein titin are found commonly in 
MG patients with thymoma, and late onset MG patients without thymoma [17]. 
 
1.1.2 Role of the thymus 
The thymus functions as an organ for shaping T cell repertoires, including negative 
selection of autoreactive thymocytes. Thymic abnormalities frequently occur in MG 
patients, with about 75% of patients having hyperplasia, 10-15% with thymoma, and 
10% with normal histology [18]. Thymic hyperplasia is observed more commonly in 
younger female patients [5], whereas thymoma occurs more frequently in older patients 
and often represents more severe disease [19].  
 
Thymectomy, surgical removal of the thymus, is frequently performed on patients with 
generalized MG or severe symptoms. Thymic histopathology is examined post-
operatively. Thymectomy improves patient condition through unknown mechanisms 
[17], and reduces the frequency and severity of myasthenic crisis [20]. 
 
1.1.3 Diagnosis 
The diagnosis of myasthenia gravis is made after the presence of muscular weakness of 
the skeletal muscle or ocular-bulbar region and confirming criterion. Repetitive 
supramaximal nerve stimulation at 3 Hz resulting in an increased decrement of the 
muscle action potential evoked is often observed in myasthenic individuals [21]. A 
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more sensitive test is a single fiber EMG (SF-EMG) investigation developed by 
Stålberg and Ekstedt [22]. An edrophonium test, wherein a short acting intravenous 
anticholinesterase results in a rapid but brief improvement in muscle strength in MG 
patients, is indicative of the disease [23]. Measurement of anti-AChR abs confirms the 
diagnosis. Cases with decremental response to repetitive nerve stimulation or abnormal 
SF-EMG without anti-AChR or anti-MuSK abs are classified as seronegative MG. 
 
1.1.4 Treatment 
Treatment for MG usually begins with oral cholinesterase inhibitors, such as 
pyridostigmine bromide, which prolongs the activity of acetylcholine. Thymectomy is 
performed most commonly in early onset MG patients with generalized symptoms who 
are anti-AChR positive [17]. Immunosuppressive therapy is indicated in severe or 
progressive cases. Corticosteroids are commonly used, although often side effects are 
evident. Azathioprine may be used alone or with prednisone, and requires long term 
usage to achieve maximum effect [4]. Also, cyclosporine A, mycophenolate mofetil, 
tacrolimus, rituximab and other modern immunomodulating drugs have been 
prescribed. Plasma exchange and intravenous human immunoglobulins (IVIg) are more 
expensive treatments producing faster benefits, and are used in severe or life 
threatening cases of MG, or prior to surgery to increase patient strength [4].  
 
1.1.5 Subgrouping of patients 
Bimodal peaks of MG onset are observed, with the first being younger patients who are 
anti-AChR positive with thymic hyperplasia [24]. Female patients are most prevalent in 
this group (3:1). The second peak, in patients with later onset disease, frequently with 
thymoma, has a slightly higher ratio of male patients (1.5:1) [8]. The age of onset of 
patients has been increasing in the last two decades [25]. Division of patients using age 
of onset into early onset MG (EOMG) and late onset MG (LOMG) can be used. There 
is a lack of consensus on the age which most accurately divides these groups, with 
some publications using 50 years of age [26][27] and others using 40 years of age [28].  
 
Clinical classification can also be made solely based on disease class (ocular, 
generalized/severe) or thymic histopathology (normal, hyperplasia, thymoma). The 
presence of anti-AChR abs, and HLA alleles, are also used to create subgroups to 
measure association. 
 
1.1.6 Genetic associations 
HLA associations are common in MG, with the HLA-B*08 (B8) and DRB1*03 (DR3) 
being associated as well as the HLA A1, B8, DR3, DQ2 “8.1” haplotype [29-32]. The 
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aforementioned EOMG group and thymic hyperplasia are most strongly associated 
with these alleles/haplotype, and LOMG is associated with HLA-B*07, DRB1*02 (B7, 
DR2) [33][34]. Other genetic associations to MG include IL-1 [35][36], CTLA-4 
[37][38], IL-10 [39][40], TNF-α [41], the acetylcholine receptor subunit alpha 
(CHRNA1) [42][43] and PTPN22 [44]. 
 
1.2 SELECTIVE IGA DEFICIENCY 
Selective IgAD is defined by serum IgA levels lower than 0.07 g/l with normal levels 
of IgG and IgM. It is the most common primary immunodeficiency in Caucasian 
populations, with a frequency of 1:600. A large scale screening of blood donors for IgA 
in Sweden occurring over many years [45] has found 47 IgAD of 28,413 samples 
measured, indicating a background rate in Sweden of 1:604 individuals.  
 
IgA comprises the largest proportion of immunoglobulins, and is secreted in mucosal 
linings. Involved in innate immunity, IgA prevents microbes entering the body from 
multiplying, particularly in the respiratory and gastrointestinal tracts [46]. Many IgA 
deficient individuals may be asymptomatic, while others may suffer from recurrent 
infections, allergies or autoimmunity [47]. Normal levels of IgA are approximately 2-3 
g/l in serum [46].    
 
An increase in the HLA-B*08, DRB1*03, DQB1*02 (B8, DR3, DQ2) haplotype has 
been reported in IgAD patients [48][49], as well as increases in DR7, DQ2 and DR1, 
DQ5 [50]. It has further been previously suggested that the prevalence of IgAD in HLA 
B8, DR3, DQ2 homozygous individuals is approximately 13% (RR=77.8) [51-53]. The 
DR15, DQ6 haplotype confers strong protection against the development of the disease 
[50][54][55]. 
 
IgAD occurs concomitantly with autoimmunity, such as RA [56][57], SLE [58] and 
juvenile diabetes mellitus [59], possibly due to overlapping HLA associations. It has 
also been suggested that IgAD may be caused by autoimmune mechanisms [60].  
 
1.3 MAJOR HISTOCOMPATIBILITY COMPLEX 
The major histocomptability complex (MHC) is a 3.6 Mb, gene rich region of 
chromosome 6 which plays a crucial role in the recognition of self and non-self. In 
humans termed human leukocyte antigen (HLA), class I and class II MHC genes 
encode antigen presenting proteins expressed on cells of the immune system [61]. 
HLA-A, B and C belong to Class I, and HLA-DPA1, DPB1, DQA1, DQB1, DRA1 and 
DRB1 belong to Class II. Class I molecules are expressed on most somatic cells, 
 12 
whereas Class II molecules are expressed on antigen presenting cells. The highly 
polymorphic nature of the MHC and the number of HLA allele combinations makes 
each individual immunologically unique (with the exception of MZ twins) [62]. 
 
In response to the existence of a pathogen, antigen presenting cells load digested 
peptides onto Class II molecules after phagocytosis for display to T-cells. When a T-
cell recognizes a peptide, B-cells are stimulated to produce antibodies against the 
pathogen. Since the antigen recognizing capabilities of T-cells are immense, 
autoreactive T-cells may arise, which are normally negatively selected; however, in 
autoimmunity, thymocytes which strongly bind to self antigens escape this process 
[63]. 
 
HLA alleles have been associated to virtually all forms of autoimmunity. In particular, 
the HLA B8, DR3, DQ2 haplotype, both with and without A1 (8.1 haplotype), has been 
associated with MG [64], IgAD [48][49], Graves’ disease [65], CD [66], and SLE [67]. 
 
1.4 COMPLEX DISEASE 
A disease is general termed complex if its development requires both multiple genetic 
factors as well as environmental interaction [68]. The genetic factors are typically not 
monogenic in nature; that is, there are usually many genes which act together to 
predispose the individual to a disorder. For this reason, genes are rarely discovered with 
large ORs, whereas in monogenetic disorders, such as cystic fibrosis, a single gene 
mutation is frequently responsible for causing the disorder [69].  
 
The environmental component(s) necessary to develop the disease are often unknown, 
although risk factors related to the environment exist, such as smoking in RA [70]. 
Exposure to the requisite environmental factor(s) necessary to develop the disease has 
been termed the environmental trigger, which may be a single event or an aggregate 
effect. Often this underlying genetic predisposition causes no disease manifestation for 
many years, until either a threshold of environmental exposure or a triggering event 
occurs, after which the disease manifests.  
 
Often it is unclear whether a complex disease is a single disorder or a collection of 
different disorders with overlapping symptoms. Rheumatoid arthritis (RA), for 
example, is often referred to as a “syndrome of diseases” due to both the various forms 
of the disorder, and the variety of genetic associations that have been found to 
contribute to the disease [71]. 
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Despite advances in genotyping and sequencing technologies, with increases in 
throughput and decreases in costs, new methods to determine the manner in which 
genetics predispose to complex disease have largely not been undertaken.   
 
1.4.1 Threshold model 
The threshold model of complex disease attempts to explain the interaction between 
genetic and environmental effects (Figure 2) [72].  Individuals are assumed to fit a 
normal distribution, which shifts toward a threshold based on the number of 
susceptibility genes present in the individual. This threshold, which represents disease 
development, is itself influenced by environmental factors. An increase in genetic 
factors predisposing to the disease increases the individual’s chances of developing the 
disease accordingly, whereas exposure to environmental factors reduces the threshold 
[72]. This assumes an additive effect of susceptibility genes, wherein each gene has a 
fixed effect and do not interact [73]. A purely additive model assumes that the risk is 
constrained by contributions from risk alleles and environmental elements, and not 
probabilistic [74].  
In
d
iv
id
u
al
s Threshold
Disease liability
Proportion 
affected
 Figure 2. The threshold model of complex disease 
 
This model has the weakness of assuming that the genetic contribution to disease 
development is additive; that is, the presence of risk alleles shift the distribution either 
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toward or away from the threshold. Furthermore, the risk of developing disease is 
stochastic, and all individuals with some risk allele(s) may have a small probability of 
disease development. Both of these conditions may be false if predisposition requires a 
precise combination of genetic factors.  
 
Multiplicative models attempt to correct for this lack of gene-gene interaction, and 
thereby account for epistasis present in measured genes/loci [73]. However, these 
models have failed experimental validation [75], and often explain only a small 
proportion of overall genetic predisposition to a disorder. 
 
1.4.2 Rothman pie diagram 
A model which alleviates concerns with the threshold model was created by Rothman, 
which he referred to as a pie diagram of sufficient disease causes (Figure 3) [76]. This 
model presumes that disease which appears in an individual is the result of several 
sufficient causes, where each cause is denoted by a letter. An individual who 
accumulates the correct number/combination of sufficient causes will develop disease, 
and one who does not will not develop disease. 
 
 
               
Figure 3. Rothman pie diagram of sufficient causes of disease 
 
The pies are therefore different for various underlying forms of disease, and each 
complex disease may be caused by many different pies. Furthermore, these causes may 
be genetic in nature, or may contain external factors, such as the environment. 
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1.5 TWINS DATA 
Twins data has mainly been used in the context of classical twins studies (CTD), in 
which the pairwise concordance is given by C/(C+D), where C indicates a concordant 
twin pair and D indicates a discordant twin pair [77].  
 
The twin concordance rate in monzygotic (MZ) twins is defined as an additive 
genetic effect (VA) plus an environmental effect (VC). The dizygotic twin (DZ) 
concordance rate is given as ½VA+VC, due half of all genes shared, and solving for 
VA yields a genetic component equal to twice the difference in concordance between 
MZ and DZ twins [2 * (MZ-DZ)]. This is often used as a proxy for the maximum 
genetic component expected to be observed in case-control studies [78], and is also 
termed “heritability”. This, however, does not yield any information about the 
underlying predisposition, nor is it informative if the difference between MZ and DZ 
concordance is greater than 50%. 
 
1.6 CONCOMITANT AUTOIMMUNITY 
Autoimmune disorders are caused by the production of auto-antibodies directed against 
various structures of the body. The severity and symptoms of these diseases are diverse, 
and frequent diagnosis of concomitant autoimmune disorders suggests interplay 
between their various causes. Although the means by which the diseases manifest 
themselves are largely unknown, many key genes conferring predisposition to various 
forms of autoimmunity have recently been discovered. Due to the overlap of some 
genetic factors predisposing to autoimmune disorders, it is common to test a gene or 
SNP associated with one disorder to other disorders, as this provides an immediate 
target for measuring if a similar effect exists.  
 
Many autoimmune disorders have high prevalence of concomitant autoimmunity, 
possibly due to similar genetic factors resulting in common mechanisms. In MG, SLE 
has been known to occur in patients more than expected by chance [79-81], and the 
appearance of SLE in MG patients who have undergone thymectomy has been reported 
[82][83].  
 
Other autoimmune disorders reported at a greater rate in MG patients include 
thyroiditis/Graves’ disease [84-89], and RA [86]. 
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1.7 PTPN22 
The PTPN22 (Protein tyrosine phosphatase, non-receptor type 22) gene is located on 
chromosome 1p13.2, and contains a functional SNP in exon 14 (1858C>T, R620W, 
rs2476601) which replaces an arginine with a tryptophan. This polymorphism has been 
associated with several forms of autoimmunity, such as T1D [90][91], RA [92] 
[93][94], SLE [95][96] and Graves’ disease [97]. The polymorphism was also reported 
to be overrepresented in a subgroup of MG (patients without thymoma or anti-titin abs) 
[44]. However, studies on several other autoimmune diseases, such as MS [98][99], 
Crohn’s disease [98], and primary Sjögren’s syndrome [100], reported no association 
with the SNP. 
 
PTPN22 consists of an N-terminal phosphatase domain and C-terminus with several 
proline-rich motifs [101]. The missense mutation rs2476601 alters the proteins 
interaction with the negative regulatory kinase Csk, thereby altering the T-cell response 
[102]. A recent study which reported association of this mutation with T1D suggested 
that higher catalytic activity of the phosphatase (gain-of-function) resulted in more 
efficient inhibition of TCR mediated activation of T lymphocytes, and therefore 
reduced IL-2 production [103].    
 
The large number of autoimmune disorders association with the rs2476601 SNP makes 
it a candidate autoimmune gene which might underlie common disease mechanisms. 
This may be in part due to its role as a functional variant without largely deleterious 
consequences. 
 
1.8 CIITA 
The MHC class II transactivator (MHC2TA, CIITA), located on chromosome 16p13, 
contains four alternative promoters which exhibit cell-type specific activity [104].  The 
gene is a transactivator of MHC class II genes, expression of which is crucial for cell 
collaboration and induction of immune responses, whereas lack of expression is 
associated with the severe immunodeficiency disease bare lymphocyte syndrome 
(BLS) [105].  
 
The type III promoter (-168A/G, rs3087456) was reported to be associated with 
rheumatoid arthritis (RA), multiple sclerosis (MS) and myocardial infarction (MI) 
[106]. This SNP was shown to reduce transcription levels of CIITA ex vivo in human 
leukocytes stimulated with interferon-. Further, the same study also demonstrated 
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lowered expression of MHC class II molecules in rats based on CIITA polymorphisms 
[106]. 
 
Due to the direct effect on MHC molecule expression, as well as association to well 
characterized autoimmune disorders (MS and RA), the polymorphism is interesting for 
association studies in autoimmunity, including replications studies in additional 
cohorts. Despite this, the role of the SNP in MG has not been established. 
 
1.9 CD45 
CD45, also called protein tyrosine phosphatase, receptor type C (PTPRC), is located on 
chromosome 1q31-32. The receptor belongs to the protein tyrosine phosphatase family, 
which has been shown to be involved in cell growth, differentiation and signaling 
[107]. Heavily expressed on T-cells, it has been shown to play a role in T-cell receptor 
signal transduction and activation as well as in thymic selection of T-cells, both 
important features in the development of autoimmunity. A lack of CD45 expression 
results in severe immunodeficiency [108][109].  
 
The gene produces eight known isoforms via complex alternative splicing which is cell 
specific. One such isoform, containing exon 4 (CD45RA+), is expressed mainly by 
naïve T-cells, while an isoform with exons 4-6 spliced out (CD45RO+) is expressed by 
most memory T-cells [107].  
 
A low frequency SNP, rs17612648 (77C/G), has been reported to disrupt an exonic 
splicing factor, thereby causing the failure of exon 4 to splice out. This leads to higher 
levels of CD45RA expression on memory T-cells of homozygous individuals [110]. It 
has been suggested that this may provide a mechanism to alter the T-cell activation 
threshold, providing a mechanism for the development of autoimmunity [111]. CD45 is 
therefore a potential common autoimmunity gene, although its role in MG has not been 
determined. 
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2 AIMS 
 
2.1 SPECIFIC 
 
The most specific aim of the thesis is to investigate genetic factors which may 
predispose individuals to autoimmune disorders, in particular MG, and IgAD. The 
overlap between the two disorders and the role of HLA associated genes is a direct 
goal. 
 
2.2 GENERAL 
 
A more broad aim of the thesis is to use the results in MG and IgAD, together with 
published information, to further understand complex disease predisposition. Using 
autoimmune disorders, most of which have complex etiology, a common basis for 
autoimmunity may be investigated. 
 
Furthermore, these studies yield insight into the inherited basis of complex disease, and 
a model of complex disease can be created to aid in future research. 
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3 MATERIALS AND METHODS 
 
3.1 PATIENT COHORTS 
3.1.1 MG 
The myasthenia gravis patient cohort used in these studies included samples 
accumulated over many years. The diagnosis of MG was made by the neurologist, and 
blood and/or serum was collected during visits at the Neurology department. Patients 
were analyzed for anti-AChR abs routinely at the first patient visit, and occasionally 
during subsequent visits at the physician’s discretion. A total of 547 MG patients were 
used in these studies. Healthy controls consisted primarily of self-reported healthy 
blood donors. All patients gave informed consent and use of patient and control 
materials was approved by the Karolinska Institutet and The Regional Ethical Review 
Board.  
 
Clinical subgroups of MG were made according to the Oosterhuis-Jaretzki scale, 
thymic histopathology, age at onset of disease, etc. as reported by the primary 
physician.  
 
3.1.2 IgAD 
Five hundred thirty-three IgAD subjects from the immunodeficiency unit at the 
Karolinska University Hospital were included in the study for determination of HLA 
types. All patients were identified or referred by fulfilling the criterion for IgAD (IgA < 
0.07 g/l with normal IgG and IgM). 
 
3.1.3 8.1 haplotype 
Three groups of Caucasian subjects (n=117), homozygous for the B8, DR2, DQ2 
haplotype, were obtained from the following sources: 78 from the Swedish volunteer 
bone marrow registry (www.tobiasregistret.se), 30 from routine tissue typing of 
transplantation relative screening and 9 population based controls from the 
Rheumatology Unit, Department of Medicine at the Karolinska University Hospital. 
All subjects were chosen solely on the basis of the presence of the haplotype in 
homozygous form, and without any prior knowledge of IgA levels. 
 
3.2 DNA EXTRACTION 
Genomic DNA was extracted from whole blood using the phenol-chloroform or salting 
out method. 
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3.3 ELISPOT 
Peripheral blood mononuclear cell (PBMC) isolation was performed as previously 
described [112]. ELISpot was conducted on 100 randomly selected MG patients 
without previously knowledge of genotype to enumerate the number of cells secreting 
IL-2, IFN-γ or IgG against the human AChR receptor [112]. 
 
3.4 GENOTYPING 
Measurements of genotypes were performed at the Mutation Analysis Facility at the 
Karolinska Institutet, using matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) mass spectrometry [113] (SEQUENOM Inc., San Diego, California, 
USA). Primers specific to the genotypes were synthesized, and genotyping utilized 
IPLEX chemistry. 
 
Confirmation of genotypes, when utilized, were performed by direct “Sanger” 
sequencing at Macrogen, South Korea. For rs17612648, the primers used were 
CTGGGAGGAGCATACATTTAGG and AGCACTAGCATTATCCAAAGAG. 
 
3.4.1 IMAGEN genotyping 
As part of the IMAGEN project, genotyping was conducted on 1535 SNPs for 453 MG 
samples, 270 IgAD samples, and 673 healthy controls using a custom array [114]. After 
quality control, this panel contained 1288 SNPs, of which 1230 were in the extended 
MHC region. 
 
3.4.2 Illumina genome wide genotyping 
Genome-wide scans for both patient cohorts and controls were conducted as part of a 
separate study. Five MG patients and 6 controls homozygous for the HLA B8, DR3, 
DQ2 haplotype were typed as part of a larger material using the Illumina
 
HumanHap300 (317K) genotyping BeadChip. A further 18 IgAD patients and 9 
controls homozygous for the same haplotype were genotyped using this platform. An 
additional 8 IgAD patients and 15 healthy controls, also homozygous for the HLA B8, 
DR3, DQ2 haplotype were genotyped using the Illumina
 
Human610-Quad (620K) 
genotyping BeadChip array. 
 
Quality control was conducted using PLINK [115] to remove SNPs which were above 
a given missingness in cases or controls (>10%), not in Hardy-Weinberg equilibrium 
(p<0.001) or below a minor allele frequency threshold (<1%).  As a last control, the 
number of missing samples for each of cases and controls were compared to those 
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successfully typed (for the entire cohorts), and a p-value of missingness between cases 
and controls of less than 0.001 were discarded. 
 
3.4.3 SNP mapping 
For IgAD and control comparisons, two separate SNP maps were constructed using 
genotyping data. The first map used 1,116 SNPs across the MHC from upstream of 
HLA-A to downstream of HLA-DP. These SNPs were extracted from an Illumina 
custom array panel described previously [114]. An additional 896 SNPs across the 
same region from the GWAS data were included. Merging the data sets and removing 
duplicate SNPs left a total of 1,718 unique SNPs across the MHC. Swedish IgAD 
patients, homozygous for the HLA B8, DR3, DQ2 haplotype (n=18), were compared to 
population based controls (n=9) with normal IgA levels who were homozygous for this 
haplotype. 
 
The second IgAD SNP map consisted of a total of 3,874 SNPs across the same region 
using the higher density array. This SNP map included additional HLA B8, DR3, DQ2 
homozygous Swedish IgAD patients (n=8) and IgA sufficient donors from the Swedish 
volunteer bone-marrow registry (n=15). 
 
For MG, a single SNP map consisting of 5 patients, 6 healthy controls and 10 IgAD 
individuals was created, using 1,719 SNPs, including 897 SNPs from merged GWAS 
data and 1,116 SNPs from the custom panel, with duplicate entries removed. 
 
The data were extracted in PED/MAP format and merged using custom PERL scripts 
(www.perl.org). Conversion to genotype format (0,1,2) was conducted with 
EIGENSTRAT [116], and the data were color coded for visualization with MS Excel. 
 
3.5 HLA TYPING 
Anonymized control data for HLA alleles was obtained from the Swedish volunteer 
bone marrow registry (www.tobiasregistret.se). The data consists of 40,789 
participants, HLA typed for HLA-B (n=40,789), HLA-DR (n=23,609) and HLA-DQ 
(n=1193). HLA-A data has not been collected in this database; therefore, the frequency 
of HLA-A alleles in Sweden from a previous publication using 252 unrelated Swedish 
individuals was used [117]. 
 
3.5.1 Imputation 
A method of HLA imputation based on 3 SNP tagging was used to infer the HLA type 
of samples. As part of the IMAGEN project [118], most MG samples were typed at 
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1288 SNPs, 1230 of which were tag SNPs across the MHC [118]. Using this 
information, imputations of HLA-A, B, DR and DQ were obtained using a previously 
validated method shown to have a 95% accuracy in imputing 4 digit types in European 
populations [114][119], of which 2 digit types were used.  
 
HLA types shown to have mismatches from previously typed samples via 
PCR/serology were repeated with PCR-SSP. These included HLA-A*3101, B*3501, 
B*4002, DRB1*401, DRB1*403 DRB1*701, and DRB1*1401. 
 
3.5.2 PCR-SSP 
PCR by sequence specific primers (SSP) is a highly accurate method to determine HLA 
types [120]. This technique utilizes standard PCR with pre-formulated plates containing 
primer pairs specific to certain HLA alleles. Different numbers of wells/primer pairs 
are required for the determination of HLA types. In these investigation, 2 digit types 
were obtained for HLA-A (24 wells), HLA-B (48 wells), HLA-DR (24 wells), HLA-
DQ (8 wells) and HLA-DR-DQ (32 wells).  
 
The PCR was conducted according to the manufacturer’s specification (Olerup SSP 
AB, Saltsjöbaden, Sweden). The PCR products were then run in 2% agarose gel stained 
with ethidium bromide for 10 minutes at 150 mA, 300 V, visualized by a UV 
illuminator and photographed. Each well has a positive control and may contain 
amplified PCR products, and HLA-A, B, DR, and DR-DQ have a negative control. 
Determination of the HLA type was made by matching wells positive for PCR products 
to interpretation tables. 
 
 
Figure 4. A typical SSP-
PCR gel. The left half of 
the gel contains products 
from the wells (ie. primer 
pairs) for HLA-B low (48 
wells), and is positive for 
bands in wells 2, 8, 9, 24, 
27, 30, 35, 36, 44, 46 and 
47. The upper right 
quadrant contains HLA-A 
low, positive for bands in 
wells 1, 2, and 4. The 
lower right quadrant is 
HLA-DR low, and has 
positive bands in wells 1, 
5, 6, 17, and 21). The 
corresponding HLA type 
is A1,2  B8,51  DR1,3 
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The kits used in these studies included the HLA-A low resolution (26F, 62G), the 
HLA-B low resolution (L21, M26, J82, N80, R56, X13, X82, 90F, 63G), the HLA-DR 
low resolution (40E, 83F), the HLA-DQ low resolution (41E, 91F) and the HLA- DQ-
DR SSP Combi Tray (K88, R60, V95, M01, M84). 
 
3.6 SERUM IMMUNOGLOBULIN LEVELS 
IgA, IgG and IgM serum levels were determined by nephelometry at the Karolinska 
University Hospital Clinical Chemistry Laboratory. Samples were considered to be 
IgAD if serum IgA was under 0.07 g/l with normal levels of IgG and IgM. 
 
3.7 STATISTICAL ANALYSES 
Association for case-control studies was determined using the χ2 test, using one degree 
of freedom for allele counts and two degrees of freedom for genotype ratios. When the 
expected value for some data was low (n<5), Yates’ correction for continuity was used. 
 
For all studies, a significance threshold α=0.05 was used. In the case of testing multiple 
SNPs or clinical subgroups of MG, correction for multiple testing error was conducted. 
The Bonferroni correction approximates the α required for a similar significance level 
when simultaneously making multiple measurements. The accepted approximation α/n 
for n tests, following from  1 − (1− α)𝑛 =∝0, was used. 
 
One-way ANOVA test for comparison of three groups and Mann-Whitney t test were 
used to analyze ELIspot data, with significance indicated by a p-value below 0.05. 
 
The odds ratio (OR) gives the ratio of the occurrence of an event in one group to the 
occurrence of the event in a second group. In case-control studies, the event is the 
genetic factor, given by allele frequencies: 𝑂𝑅 = 𝑎𝑑/𝑏𝑐 
                                         
 allele 1 allele 2 
case a b 
control c d 
 
 
The relative risk (RR) is defined as 
𝑝(𝑒𝑥𝑝𝑜𝑠𝑒𝑑 )
𝑝(𝑛𝑜𝑛 −𝑒𝑥𝑝𝑜𝑠𝑒𝑑 )
. In genetic case-control studies, the 
relative risk describes the ratio of the proportion that develop the disease with the 
genetic factor (exposed) to the proportion who develop disease without the genetic 
factor (non-exposed). This requires an unbiased measurement from the population of 
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those with and without the genetic factor, followed by subsequent examination for 
clinical diagnosis of disease. 
 
3.8 POWER CALCULATIONS 
The statistical power of a study is defined as the probability of rejecting a false null 
hypothesis, and is therefore equal to (1-β), where β is the false negative rate. The 
calculation of power is highly dependent on the sample size as well as the minimum 
effect size that is expected to be detected. In genetic studies, this is represented by the 
allelic odds ratio observed. The calculation is typically reported as the OR 
corresponding to an 80% power in case-control association studies at a given α. 
 
For the studies presented, power was calculated by the Power Calculator for Two Stage 
Association Studies” (http://www.sph.umich.edu/csg/abecasis/CaTS/) [121]. The 
background allele frequency was estimated by the aggregate control MAF reported, 
with significance level α=0.05. The frequency of MG in the population for calculations 
was 1:10,000. 
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4 RESULTS AND DISCUSSION 
 
4.1 PTPN22 IS ASSOCIATED WITH MG 
We genotyped the PTPN22 1858C>T mutation (R620W, rs2476601) in 409 MG 
patients and 1557 matched healthy controls. The allele frequencies were associated to 
all MG patients (n=409) (p=2.7x10
-4
, OR=1.52) as well as anti-AChR abs positive 
patients (n=350) (p=4.9x10
-4
, OR=1.52).  
 
In patients with thymic hyperplasia (n=142), a similar association of the polymorphism 
was observed (p=1.4x10
-4
, OR=1.87), with an increase in the OR in patients with both 
thymic hyperplasia and anti-AChR abs (n=128) (p=6.6x10
-5
, OR=1.96).  
 
We furthermore examined IL-2 and IgG producing cells, indicative of anti-AChR abs 
secretion, after antigen activation in 100 randomly chosen patients with different 
rs2476601 genotypes. Enumeration of cells secreting IL-2, IFN-γ, or IgG did not differ 
between PTPN22 genotypes in medium alone. However, in cells incubated with auto-
antigen, there were increases in IL-2 producing cells (p=0.002) and IgG secreting cells 
(p=0.004) in patients carrying the T allele.   
 
These results confirm the association of rs2476601 with MG, and suggest that the gene 
may play a role in autoimmune disorders through a common mechanism. While 
previous findings suggested that the mutation may be a gain-of-function variant, our 
data indicate that the mutation may be a loss-of-function variant in MG, resulting in IL-
2 production and T-cell proliferation. This effect may indicate a disease specific 
mechanism of the mutation, or that other genetic factors may influence expression 
through epistasis. 
 
4.2 CIITA IS NOT ASSOCIATED WITH MG 
Genotyping of 446 MG patients and 1866 controls for rs3087456 was conducted, and 
patients were stratified according to common clinical subgroups. No statistically 
significant difference was observed between MG patients and controls for either 
allele frequencies (p=0.092) or genotypes (p=0.251). The strongest associations were 
in the ocular and LOMG subgroups, with uncorrected p-values of 0.040 and 0.010, 
respectively. However, they yielded non-significant p-values when compared with the 
multiple testing corrected significance threshold of 6.25x10
-3
, corresponding to 8 
tests. 
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Furthermore, when examining replication studies conducted on the SNP, only 4 of 26 
reported significant association, including 2 of 10 in RA cohorts (Table 2). One of the 
positive RA replication studies further reported association with an increase in the 
major (A) allele [122] in a Japanese population, drawing the proposed mechanism into 
question. 
 
Disease Number of cohorts Positive assoc. 
RA 10 2 
SLE 3 0 
MS 4 0 
WG 1 0 
MI 1 0 
AAD 2 2 
JIA 1 0 
IBS 1 0 
CVID 1 0 
IgAD 1 0 
CD 1 0 
Total 26 4 
 
Table 2. A summary of replication studies of the CIITA SNP rs3087456 in autoimmune 
disorders 
 
Our control cohort had a significantly higher frequency of the minor (G) allele that the 
original study reporting association of the SNP to autoimmunity [106] (0.266 and 
0.216, respectively, p<10
-5
). We also compared MG allele frequencies to this control 
material. However, the MG group did not show a statistically significant association 
when using the original study’s control frequency. 
 
These findings indicate that the CIITA SNP rs3087456 is not associated to MG, that its 
role in autoimmunity may not be as strong as previously thought, and that other factors 
may regulate CIITA expression in patients with autoimmunity. 
 
4.3 CD45 IS NOT ASSOCIATED WITH MG 
The CD45 SNP rs17612648 was genotyped in 446 MG patients and 2303 matched 
controls. Allelic variants of rs17612648 were not associated with myasthenia gravis in 
the patient group as a whole (p=0.199), although the minor (G) allele appears slightly 
more frequently in MG patients than in controls (1.91% compared with 1.35%). No 
subgroup of MG associated with the SNP (p>0.260, corrected), despite a slightly 
elevated minor allele frequency in most subgroups. In patient subgroups, the LOMG 
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HLA B7 (0.91% MAF) and DR2 (0.81% MAF) subgroups had a lower frequency of 
the G allele than the control population (1.35% MAF), although, due to the low allele 
frequency, each group contained only one heterozygous case. 
 
A blood donor control sample was found to be homozygous for the G allele, and 
confirmed by sequencing. Due to the presumed deleterious effect of homozygosity of 
this allele [123], a serum sample was tested in order to determine if autoantibodies 
were present. ANA antibodies (Anti-Nucleosome, Ribosomal P, RNP68, RNP A, Scl-
70, Sm, SmRNP, SS-A(Ro52), SS-A(Ro60), SS-B, Centromere, Jo-1 and dsDNA) 
and ANCA antibodies (Anti-PR3, MPO and GBM) were not demonstrated. Serum 
immunoglobulin levels were also normal (IgM=0.7 g/l, IgG=9.7 g/l, IgA=1.7 g/l). 
Due to restrictions in the ethical permission of the study, requesting anonymous 
control samples, material for additional analysis, including CD45 expression, could 
not be obtained. 
 
Disease Number of cohorts Positive assoc. 
RA 9 2 
CVID 3 0 
IgAD 3 0 
TID 2 0 
Graves 1 0 
SSc 2 1 
SLE 1 0 
MG 1 0 
AIH 2 1 
Total 24 4 
 
Table 3. Summary of replication studies of the CD45 SNP rs17612648 in autoimmunity 
 
Only 4 of 24 replication cohorts of rs17612648 with autoimmunity have reported 
association of the SNP with a disorder, including 2 of 9 in RA (Table 3). In a recent 
MG study, although the SNP was not present in the cohort, ratios of CD45RO to 
CD45RA CD8+ T-cells were found to be significantly lower in patients with late onset 
MG (LOMG) as well as in T-cells in patients with thymoma [124]. These differences 
suggest an alteration in CD45 expression independent of the rs17612648 SNP, and 
provide evidence that CD45 splicing may be regulated by other factors. Furthermore, it 
has been demonstrated that human/mouse somatic cell hybrids carrying only the mutant 
(G) allele are still able to generate CD45RO [125]. 
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The discovery of a homozygous blood donor without obvious autoimmunity suggests 
that the mutation may not have strong deleterious effects. The lack of association of the 
SNP with MG, as well as a lack of replication, indicates that the mutation’s role in 
autoimmunity may have to be reevaluated.  
 
4.4 8.1 HAPLOTYPE IN IGAD 
Of 117 individuals homozygous for the B8, DR3, DQ2, 2 were found to be IgAD 
(1.7%), far less than previous studies have reported. The approximate relative risk of 
homozygosity for the haplotype for the development of IgAD can be estimated using a 
previous population based screening for IgAD, which found 10 IgAD individuals (9 
measured and all non-homozygous) in 6955 blood donors in Sweden. Based on these 
data, the relative risk has been calculated to be 11.89. The large discrepancy between 
our results and previous studies (RR=77.8) may be due to inaccuracies in serological 
typing, low samples sizes or publication bias.  
 
The frequency of the haplotype was much higher in our cohort of 421 IgAD patients 
(25.9%) than in the background in Sweden using data from the volunteer registry 
(8.2%) (p=5.1×10
-74
, OR=3.90). Among homozygotes, The frequency of the haplotype 
was 6.9% in the IgAD group compared with 0.7% in the background population 
(p=1.4×10
-47
, OR=11.12). SNP maps were unable to elucidate any differences in 
homozygosity between IgAD individuals and controls. 
 
Concomitant haplotypes were examined, with DR7 found to be more frequently present 
in heterozygotes (21.3%) compared to controls (8.5%) (p-val = 3.5x10
-6
 with 
Bonferroni correction for 10 tests), with the result possibly due to independent 
association of DR7 with IgAD.  
We also addressed the hypothesis that a rare, more highly penetrant variant of the 8.1 
haplotype might explain the data. Assuming that the Swedish volunteer bone marrow 
registry represents a cross section of the Swedish population, the frequency of a 
putative disease predisposing rare variant of the B8, DR3, DQ2 haplotype was 
estimated to be 18 of 3,880 copies (0.46%). Sequencing this haplotype in homozygous 
patients and controls is a logical extension of these experiments, which could determine 
the region(s) of association more definitely. 
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4.5 AUTOIMMUNITY IN MG – NO ASSOCIATION WITH IGAD 
In 547 MG patients, concomitant autoimmunity was diagnosed in 87 (15.9%), far great 
than in the general population (approximately 5-8% in developed countries [126]) 
(Paper V, Figure 1a). 
 
Two of 482 MG patients were found to be IgAD, not significantly increased from the 
background prevalence (p=0.14). Assuming that all individuals with one B8, DR3 and 
DQ2 contain this haplotype, the frequency of the haplotype is 9.8% in controls, 25.5% 
in IgAD patients, 15.1% in MG and 23.8% in EOMG patients. This corresponds to p-
values of 1.5x10
-33
 in IgAD, 8.1x10
-6
 in MG and 1.9x10
-16
 in EOMG. The haplotype 
was not significantly increased in the 87 MG patients with concomitant autoimmune 
disorders (13.0%, p=0.22) as compared with MG patients without concomitant 
autoimmunity. 
 
In heterozygous HLA B8, DR3, DQ2 patients with MG and concomitant 
autoimmunity, an increase in DR1, DQ5 (33.3% compared with 8.9% of controls; 
p=2.5x10
-3
) occurs, although the number of patients with this haplotype is low (n=5). 
This haplotype does not occur in the two MG patients with IgAD (DR13, DQ3 and 
DR11, DQ3). 
 
Despite borderline significant p-value (0.049), thymectomy does not appear to 
increase susceptibility of MG patients to developing other autoimmune disorders, as 
22 of 57 thymectomized patients developed their disorder before thymectomy. Since 
the rate of EOMG is somewhat higher in patients with additional disorders (57.5% 
and 48.2%, respectively), it is possible that EOMG may be influenced by common 
autoimmune mechanisms which increase the risk of additional disorders. No evidence 
was found that thymectomy increases predisposition to SLE, as 2 cases occurred 
before surgery and 3 after. 
 
The SNP map for MG patients (n=5), controls (n=6) and IgA patients (n=10) 
homozygous for the B8, DR3, DQ2 haplotype did not display any appreciable 
differences, with all individuals being homozygous through the region with some slight 
heterozygosity. 
 
In order to visualize the overlap of genetic factors in autoimmunity, several classical 
autoimmune and related disorders were selected for assessment of published genetic 
association using “A Catalog of Published Genome-Wide Studies”, a public database of 
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all GWAS results to date (www.genome.gov/gwastudies) [127]. Autoimmune and 
inflammatory disorders examined included celiac disease, Crohn’s disease, IgAD, MS, 
psoriasis, RA, SLE, systemic sclerosis, T1D and ulcerative colitis, and SNPs with 
reported association of p<10
-5
 in at least one study were cross referenced in all studies 
and charted. Regions of strong association to large number of autoimmune disorders, 
particularly the HLA, are visible. The full map of results is given in Table 1 of Paper 
V. The patterns of genetic association highlighted by this map illustrate that several 
regions of strong association to multiple disorders exist, such as the HLA, PTPN22, etc. 
However, for some diseases, very few strongly associated non-HLA genes are visible 
(ie. IgAD and systemic sclerosis). Investigating the overlap in genetic contributing to 
autoimmune using novel methods for multi-gene analysis may therefore be necessary to 
explain the nature of disease predisposition. 
 
4.6 TWINS CONCORDANCE RATES AND COMPLEX DISEASE 
PREDISPOSITION 
Although many genes are associated to complex diseases, the frequency of the 
predisposition and environmental component to such disorders is unclear. A logical and 
useful step is to infer information from twins data that can be used to estimate this 
information. It is possible to estimate the predisposition and environmental trigger 
frequencies by first assuming that MZ twins share the underlying predisposition for the 
disorder. The probabilities of twin concordance can be given as: 
 
Twin 1 Twin 2 Probability 
0 0 (1- PT) * (1- PT) 
0 1 (1- PT) * PT 
1 0 PT * (1- PT) 
1 1 PT * PT 
 
where 0 denotes a twin without MG, and 1 denotes a twin with MG, with PT being the 
probability of an MZ twin with genetic predisposition developing MG and the 
probability of an MZ twin not developing MG is 1- PT. 
 
The probabilities then simplify to:  
p( (0,0) ) No twins with MG (1- PT)
2
 
p( (1,0),(0,1) ) Exactly one twin with MG 2 PT * (1- PT) 
p((1,1)) Both twins with MG PT
 2
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The rate of MZ twins concordance is given by the proportion of both twins with MG    
p( (1,1) ) to the total MZ twin pairs observed p(1,1) + p( (1,0),(0,1) ), which is equal to 
2
2
 
2 (1 )
T
T T T
P
MZ concordance
P P P

 
 
PT can be solved and is given as follows: 
T
2*
P
1
MZ
MZ


 
 
The number of regions which contribute to the predisposition can be estimated by 
assuming that the same inherited regions predispose to disease in DZ twins. We assign 
the probability of dizygotic twins (Di) inheriting the disease to be equal to that of 
monozygotic twins (Mo) multiplied by an inheritance ratio (β) and a recombination 
probability (RF) for each of n regions.  
 
 ( ) ( ) [ 1 ]np Di p Mo RF     
 
where the term RF represents the chance of recombination within the given region 
disturbing required genetic components. The previous equation can be modified by 
including separate values of β and RF per inherited disease haplotype, since these may 
have different inheritance patterns: 
 
1
( ) ( ) [ 1 ]
i
i
n
ip Di p Mo RF

     
and then including genetic modifiers, denoted as ξ with effect sizes (0<ξ<1), occurring 
m times: 
     
1 1
(1[ 1 ] )
m
i i
n
i
j
j
jp Di p Mo RF  
 
           
 
The monozygotic twin concordance rate in MG, based on a comprehensive literature 
review, is 11 of 31 pairs, or 35.5%. Of 16 dizygotic twin pairs, none were concordant 
for MG. However, due to the low number of studies, the familial rate, measured to 
between 3.8 and 7.2% [128],[129], is assumed to be an accurate estimate. 
 
The result of the predisposition calculation in MG using an MZ pairwise concordance 
rate of 35.5% is that PT, or the rate of the environmental trigger, is estimated to be 
52.4% in predisposed twins. A consequence of this calculation is that this rate can be 
used to approximate the frequency of genetically predisposed individuals in the general 
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population, by dividing the rate of incidence by PT. In the case of MG, this would make 
the overall frequency of genetic predisposition approximately 1 in 5240.  
 
When estimating the inherited regions in MG, for simplicity the term p(Di) can be 
approximated from the familial rate to be approximately 2.5% and that of p(Mo) is 
approximately 40% (MZ rate). We can thereafter determine the expected minimum and 
maximum values under the assumption that all regions must be inherited from both 
parents (β=0.25) under a recessive model or that a single copy is required (β=0.50) 
using a dominant model. Solving the equation for n using these βs (and assuming 
RF=0) gives a solution that between two and four regions are required, which are 
inherited in their entirety. 
 
The implications of these calculations are that fewer regions than previously anticipated 
appear to be required to confer predisposition to MG. These regions may be long 
haplotypes with multiple SNPs/mutations present, and it is therefore of practical 
importance to identify these haplotypes by sequencing regions of association in 
case/control studies. 
 
4.6.1 Consideration of potential sources of error 
There are several possible sources of error in estimations for MZ twins rates. First, MZ 
twin publications occur if it is known that a patient has a twin, and this is very likely to 
be reported if the twin is concordant for MG. Therefore, publications are likely to bias 
toward MZ concordance, and over report this rate. Second, studies observe only a static 
time point in patients and their families’ lives, and non-affected MZ twins might 
develop disease later in life. It is thus difficult to estimate the effects of these factors 
without a large set of data collected over time. However, publication bias is likely to 
overestimate the MZ concordance while future diagnosis of disease in a twin pair can 
only decrease the reported rate from the true rate. Although it is certain whether these 
are equal in their effects, they are most certainly opposite in misclassification. Without 
further estimation methods, we will therefore disregard these potential sources of error. 
 
4.6.2 Effect of MG subgroups 
Myasthenia gravis has important clinical subgroups which may represent distinct 
disease entities, some with stronger underlying genetic components. A notable example 
is the aforementioned associations of HLA B8, DR3 with early onset MG and HLA B7, 
DR2 with late onset MG. Since nearly all reported affected MZ twins were EOMG, 
regardless of concordance or discordance for MG, it is very difficult to determine if this 
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is a result of publication bias or if EOMG may be overrepresented among MG twin 
pairs who are concordant for MG. In order to determine the effect of potential subgroup 
disparity in concordance rates of MZ twins, we examined the strongest possible 
example and for the moment assumed that all MZ twins concordant for MG are 
EOMG, while discordant twins have similar proportions of EOMG as we observe in 
our cohort of 542 MG patients (30% EOMG). The MZ concordance rate for EOMG 
will change from 
C
C D
  to 
*(0.3)
C
C D
, due to a 30% proportion of EOMG. Thus, 
the previous data gives an MZ concordance rate of 64.7% and increases PT to 0.79. 
While this represents an extreme case, the net result would be an increase in the 
proportion of the population with disease predisposition who develop the disease, and a 
more frequently encountered environmental trigger. This effect is likely to be more 
modest, however, since the lack of reported MG twin pairs with late age of onset does 
not definitely bias the twin calculation toward EOMG.  
 
4.6.3 Epigenetic effects 
Epigenetic changes are commonly defined as those that are not stably inherited through 
DNA alterations, and often refer to chromatin remodeling due to DNA methylation and 
histone modifications such as acetylation, methylation, phosphorylation and 
ubiquitination [130]. These changes have been hypothesized to be a potential 
underlying component of complex disease, that may or may not work in tandem with 
genetic predisposing factors. Since monozygotic twins have similar genetics, but may 
vary in epigenetic patterns, this could be a potential cause of variation explaining twin 
concordance/discordance. However, a recent study investigating the epigenetic patterns 
of three pairs of MZ twins discordant for MS, using high density SNP profiling and 
sequencing of mismatching polymorphism, determined that epigenetic patterns did not 
vary significantly between identical twins [131]. In fact, only 2 to 176 differences were 
noted in the methylation of 2 million CpG dinucleotides, whereas unrelated individuals 
contain approximately 800 such changes. It is therefore likely that at least DNA 
methylation is not a primary cause of MZ twin disease discordance.  
 
Epigenetic changes may be determined, as least partially, by genetic regulation 
mechanisms. An individual may inherit certain, as yet unidentified, genes which 
stimulate an increase or decrease in methylation or histone modification in certain 
tissues. These regulation patterns may affect levels of gene expression involved with 
disturbed equilibrium in the development of complex disorders. Should such a 
mechanism occur independently of the genetic predisposing elements, the effect would 
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be comparable in all twin pairs, and could therefore be considered similar to 
environmental factors. However, if epigenetic factors occur in tandem with certain 
required genetic predisposition, they can be considered to be genetic modifiers, thereby 
increasing the risk of a threshold of activation occurring. Thus, the requirement of 
epigenetic factor(s) for the development of MG would similarly reduce the number of 
genetic predisposing regions present. 
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5 TOWARD A MODEL OF COMPLEX DISEASE 
 
5.1 BASIS AND MODEL ASSUMPTIONS 
It is clear from previous investigations that associations of genes with complex disease 
are few in number relative to their effects. A genome-wide study which found 20 loci 
which influence adult height estimated that these variants explain 3% of the population 
variation [132], and it was recently estimated that based on this data, 93,000 SNPs 
would be required to explain 80% of height variation [133]. This highlights the 
potential pitfalls of assuming an additive effect of risk loci to explain phenotype, and 
the need for more advanced models of complex disease which can combine genetic risk 
factors.  
 
The association of a particular SNP with a disorder also yields little information about 
the increased risk for the individual to develop the disease. While the relative risk can 
be calculated, due to the effects explained above, there remain many individuals with 
the risk allele who do not develop disease; conversely, many individuals with disease 
do not possess the risk allele. Therefore, inclusion of the SNP into an explanation of 
disease pathogenesis is incomplete without further information about the network or 
pathway affected. A model of complex disease will therefore be formulated which 
considers genetic predisposition, gene-gene interaction, environmental factors, disease 
subclasses and genetic modifiers.  
 
Assuming subclasses based on clinical disease phenotypes is unsuitable, particular for a 
disease such as MG, wherein classification can change with treatment, and overlap of 
subgroups exists. The predisposition is therefore assumed to fit pie model of underlying 
genetic predisposition, wherein the environmental factor(s) are considered separately. 
This is valid if certain factors are required together; that is, if they are a necessary but 
not sufficient condition to develop disease. It is unknown how many genetic subclasses, 
or “pies” exist, in MG. These could number a few, or in the extreme case, hundreds. 
However, we will construct the model of complex disease to be insensitive to the 
number of subclasses present. The presence of genetic modifiers, which may influence 
disease development, will also be added.  
 
5.2 GENETIC FACTORS INCLUDED IN A MODEL 
The genetic predisposition of complex disease and the environmental trigger are 
necessary to occur in tandem within an individual in order to cause disease 
development. A model of complex disease must consider both of these for each 
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subclass, and construct a union of all subclasses. The genetic predisposition will be 
represented by the presence of all required factors for a particular subclass in an 
individual, while the environmental component is a continuous probability of 
encountering the event over an individual’s life. 
 
The term for environmental component, including both genetic modifiers and a trigger, 
is given as 
 *Genetic modifiers Trigger  
The genetic modifiers have previously been denoted in Paper VI as 
j occurring m 
times with effect sizes 0<ξ<1. The environmental trigger can be represented by a 
hazard rate, h(t), which is used to describe the probability of encountering an event at 
time t, given that the event has not been encountered from time 0 to time t. In this case, 
the probability is that the triggering event has not been encountered in an individual 
devoid of modifier genes. In order to include the effect of modifier genes, a Cox 
proportional hazard model can be used to represent the environmental components 
1
0( , ) ( )
m
j j
jh t h t e 
 
   
where h0(t) is the baseline hazard rate in the absence of modifiers, and the coefficients β 
provide weighting for each of j genetic modifiers, which are now denoted by Χ and are 
static over time. The cumulative hazard rate function is given by  
1
0( , ) ( )
m
j j
jH t H t e 
 
   
where H0(t) denotes the baseline cumulative hazard rate function and 
0 0
0
( ) ( )
t
H t h s ds   
The survival function is given by 
( , )( , ) H tS t e    
which signifies the probability of not having encountering the trigger from time 0 until 
time t, while the probability of encountering the trigger up to time t is 1 ( , )S t  . 
 
Predisposition for a subclass with n elements is determined by the product 
1 2* * nyy y , with yi=1 indicating the presence of each genetic element i required to be 
necessary to develop the disease, and yi=0 indicating a lack of element i. The product 
1
i
i
n
y

  equal to 1 therefore signifies disease predisposition for the subclass, and 0 a lack 
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thereof. It may follow that these yi could be further classified according to membership 
criterion, for example y1=(y11, y12,…yn) where at least one of (y11, y12,…yn) must be  
present in the individual for y1=1, this case representing an “OR” rule wherein a 
network or pathway may be sufficiently affected in multiple ways. However, this 
would simplify the number of “pies” present while confounding determination of 
genetic elements. The current model also implicitly includes this case and it will 
therefore not be included. 
 
5.3 A MODEL OF COMPLEX DISEASE 
The joint probability of both predisposition and environmental components occurring 
in the individual for the subclass is given by the product of these terms 
1
0 ( )
1
1
m
j j
jH t e
n
i
i
y e
 


 
  
 
 
  
which is equal to the environmental probability for individuals with predisposition and 
zero for individuals without predisposition, thereby removing subclasses for which the 
individual is not predisposed. This equation is similar for all subclasses, so laws of 
probability can be used to combine these over all subgroups. 
1
0 ( )
1
11
m
j j
jH t e
i
n
i ey
 


 
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 
 
  
gives the complement of disease development for a single subclass, that is, the 
probability of not developing the disease via this subclass. This is denoted p(k), and the 
product of all such p(k) for all the subclasses of disease gives the overall probability of 
not developing disease. The complement of this product is 
1
1 ( )
r
k
p k

  
and represents the combined probability of developing disease for all of r subclasses. 
Substitution yields the final probability of disease development: 
1
0 ( )
1 1
1 11
m
jk jk
j
r
H t e
ik
k
n
i
ey
 

 
  
    
  
  
  
This assumes that the baseline cumulative hazard rate function is proportional over time 
and similar across all subclasses. A further assumption is that modifier genes may have 
different weights in different subclasses, and that modifier effects are time independent. 
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5.4 MODEL IMPLICATIONS 
This model is extremely flexible and the quantitative contributions of predisposition 
and environment are capable of varying according to empirical evidence. If epigenetic 
factors are largely responsible for disease pathogenesis, the predisposition component 
may be more frequent in the population, with a larger impact of epigenetic modifiers 
present.  
 
The genetic elements and modifiers found to be acting in a particular subclass of 
disease can be used to determine how disease pathogenesis occurs. Gene-gene 
interactions in networks and pathways may be inferred, and the action of modifiers on 
these pathways may give important information about disease mechanisms. 
 
Using this model of complex disease to resolve genetic predisposition, modifier effects, 
and the survival function requires a stepwise approach that must be explored further. 
First, the genetic subclasses must be identified, by determining all groups of SNPs, 
indels, etc. which are consistently present in a large proportion of cases. Partitioning 
these into subclasses will require a large sample size and the development of novel 
analytical tools. After the identification of relevant subclasses of predisposition, the 
inclusion of potential genetic modifier data may provide a means of determining the 
model parameters, including coefficients as well as the baseline survival function.  
 
Confounding the issue of measuring the predisposition to complex disease is that SNPs 
associated to disease may be markers for the causative elements in linkage 
disequilibrium (LD) with them, thereby masking the true effects. A recent study 
determined that maximum allelic frequency variation between two SNPs with a 
squared correlation (r
2
) of 0.8 is ±0.06, which is sufficient to reduce the power of a 
study from 80% to detect Type I error of 5x10
-5
 to 60% [134]. For r
2
 =0.5, the 
maximum allele variation increases to 0.16, strongly reducing the ability to detect the 
SNP in case/control studies. 
 
Furthermore, a low number of predisposing regions in each subclass (Paper VI) points 
to an association with haplotypes and not single SNPs. Future efforts should therefore 
focus on finding these genetic elements which comprise the predisposing subclasses, as 
well as genetic modifiers present, using sequencing of cases/controls and large scale 
computational analysis tools. An emphasis on identifying epistatic effects within 
haplotypes constituting the disease predisposing regions could greatly increase 
understanding of disease causing mechanisms.  
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6 CONCLUSIONS 
 
 Myasthenia gravis is associated to the PTPN22 rs2476601 polymorphism, which 
stimulates T-cell proliferation and may therefore be a gain-of-function variant in 
MG. The mutation’s effect may be disease specific. 
 
 MG is not associated with the MHC2TA rs3087456 polymorphism, and this 
polymorphism does not appear to play a role in autoimmunity. 
 
 MG is not associated with the CD45 rs17612648 polymorphism, and this 
mutation’s role in autoimmunity may need to be re-evaluated. 
 
 Although IgAD is strongly associated with the HLA-B8, DR3, DQ2 haplotype, the 
relative risk of developing IgAD for homozygotes has been overstated and is 
approximately 11.89.  
 
 Autoimmunity disorders occur more frequently in MG patients, but this does not 
extend to IgAD. Overlapping effects in both HLA and non-HLA genes in 
autoimmunity suggest possible underlying mechanisms. 
 
 Twin data can be used to estimate complex disease predisposition/environmental 
component as well as the number of inherited regions causing disease. In MG, the 
predisposition is roughly double the rate of incidence, and the number of co-
inherited regions causing disease is 2-4. Sequencing associated regions is necessary 
to discern these haplotypes. 
 
 It is possible to model the probability of developing complex disease using the 
approach of genetic subclasses. Determining genetic factors (including modifiers) is 
necessary to solve for the underlying function. 
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7 FUTURE WORK 
 
The ultimate goal of these projects is to fully determine which genetic factors underlie 
myasthenia gravis, IgAD, and related autoimmune disorders. In order to accomplish 
this, it is necessary to 1) identify all important elements contributing to disease 
predisposition and 2) model how these factors interact. 
 
There are several projects ongoing which will attempt to further characterize both 1) 
and 2). They are: 
 
 Fine mapping of the HLA in MG patients via imputation using IMPUTE 2 and 
genome wide data. Association statistics using matched controls will then be 
used to pinpoint regions of the HLA in which disease predisposing 
polymorphisms occur. 
 
 Sequencing of the MHC from upstream of HLA-B to downstream of HLA-DQ, 
initially in 4 MG patients, 4 IgAD patients without additional disorders, and 4 
controls, all homozygous for HLA A1, B8, DR3, DQ2. This will be followed by 
additional sequencing of patients/controls as needed to clarify the role of any 
identified disease causing regions.  
 
 A case-control GWAS to identify SNPs/genes associated with MG. 
 
 A multi-SNP, multi-gene model that will create subgroups of complex disease 
directly from GWAS data, with high case/control prediction accuracy. 
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